GlassScriptPhysician profile
Marlo J Fletcher
NPI 1063833762
$837.80
in general payments reported to CMS, 2019-2025
25 companies · $394 in 2025
The $394 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.59 · 2022: $148 · 2023: $89.76 · 2024: $152 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $140.77 | 2021-2025 | |
| Boston Scientific Corporation | $79.73 | 2025 | Intracept |
| Novartis Pharmaceuticals Corporation | $73.55 | 2022-2025 | |
| Pfizer INC. | $62.05 | 2024-2025 | |
| Eisai INC. | $53.95 | 2025 | |
| Lundbeck LLC | $52.78 | 2022-2025 | Vyepti |
| Genentech USA, INC. | $38.26 | 2024-2025 | Ocrevus Zunovo, Ocrevus |
| Neurelis, INC. | $34.07 | 2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $30.23 | 2022-2025 | Ultomiris |
| Teva Pharmaceuticals USA, INC. | $27.06 | 2022-2024 | Austedo Xr |
| Janssen Pharmaceuticals, INC | $22.88 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.58 | 2022 | |
| Ucb, INC. | $17.56 | 2022 | |
| Abbott Laboratories | $16.87 | 2021 | |
| Livanova USA, INC. | $16.60 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $16.28 | 2025 | Kisunla, Amyvid |
| Azurity Pharmaceuticals, INC. | $16.26 | 2025 | Horizant |
| Arbor Pharmaceuticals, INC. | $16.09 | 2022 | |
| Acadia Pharmaceuticals INC | $15.82 | 2021 | |
| Axsome Therapeutics, INC. | $15.40 | 2025 | Symbravo |
| Sk Life Science, INC. | $15.08 | 2024 | |
| Neurocrine Biosciences, INC. | $14.67 | 2024 | Ingrezza |
| Celgene Corporation | $14.63 | 2025 | Zeposia |
| Tanabe Pharma America, INC. | $13.93 | 2024 | |
| Amgen INC. | $13.70 | 2023 | Aimovig |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marlo Fletcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.